Press release
Precision Oncology Market | Europe's Precision Pivot Accelerates - Genomics, Liquid Biopsy & AI Diagnostics Gain Ground While Health Systems Struggle With Cost, Access & CDx Adoption
Precision Oncology Market | Europe's Precision Pivot Accelerates - Genomics, Liquid Biopsy & AI Diagnostics Gain Ground While Heal
Precision Oncology Market | Europe's Multi-Omics Leap Is Rewriting the Future of Cancer Treatment
----------------------------------
The Precision Oncology Market used to be tucked deep inside clinical trial papers and molecular diagnostics workshops - a domain for specialists speaking in acronyms. That era is gone.
Europe's oncology ecosystem is rewriting its entire foundation around genomics, multi-omics, biomarker-guided therapy, AI-driven diagnostics, and reimbursement reform. Cancer care is shifting from population-level assumptions to case-level biology, and precision oncology has moved from scientific aspiration to operational mandate.
Globally, the Precision Oncology Market stands at USD 139.4 billion in 2025 and is projected to reach USD 317.5 billion by 2035 - a 7.8% CAGR.
The real story is not global growth. It is Europe's acceleration.
The continent is building an infrastructure where sequencing, digital pathology, and biomarker assays are no longer optional, but required to deliver standard-of-care treatment.
Europe is no longer following the precision oncology wave - it is shaping its clinical and regulatory architecture around it.
Get the Detailed Industry Analysis (including the Table of Contents, List of Figures, and List of Tables) - from the Precision Oncology Market Research Report: https://marketgenics.co/reports/precision-oncology-market-55206
Why Precision Oncology Became Europe's New Standard (Market Drivers)
Every genomic report accelerates a correct therapy match.
Every multi-omics profile reduces trial-and-error prescribing.
Every biomarker-guided decision cuts waste, toxicity, and cost.
Europe's precision oncology momentum is driven by:
• Adoption of NGS (Next-Generation Sequencing) in national cancer plans
• Expansion of multi-omics into clinical settings
• AI-enabled diagnostics reducing time from biopsy to therapy
• Growth of targeted biologics and ADC pipelines
• EU-wide oncology data harmonization efforts
• Rising demand for companion diagnostics (CDx) tied to drug approvals
Policy pressure is rising. The EU Cancer Mission and national precision-medicine roadmaps are aligning reimbursement to biomarker testing, not symptoms. When regulation tightens, adoption accelerates - and Europe is in the tightening phase.
Europe's High-Value Battlegrounds in the Precision Oncology Market
1. Genomics & Sequencing (NGS) Adoption in Hospitals
With genomics & sequencing representing ~44% of global market share, Europe's hospitals are scaling NGS for rapid tumor profiling.
Illumina's upcoming ultra-fast sequencing systems and Thermo Fisher's Oncomine Multi-Omics assays are becoming staples in academic and community centers.
2. Companion Diagnostics (CDx) for Targeted Therapy Approvals
Every new targeted drug approval (TROP2, KRAS G12C, HER2-low, NTRK fusions) expands Europe's need for validated diagnostic partners.
3. Liquid Biopsy Acceleration
Guardant360 CDx and emerging ctDNA platforms are reshaping monitoring, recurrence detection, and treatment adjustment, reducing reliance on invasive biopsies.
4. Multi-Omics Integration into Oncology Pathways
Europe is embracing proteomics, transcriptomics, and epigenomics to interpret tumor evolution, resistance, and therapy response - especially in lung, breast, GI, and hematologic cancers.
5. Cloud-Based Precision Oncology Platforms
AI-enabled clinical decision support now ties together tumor genomics, EHR data, and therapy libraries to recommend optimal treatments.
The battlefield is not "who offers the cheapest test," but "who offers the most clinically actionable interpretation."
To know more about the Precision Oncology Market - Download our Sample Report: https://marketgenics.co/download-report-sample/precision-oncology-market-55206
What Europe Is Doing Differently | Innovation in the Precision Oncology Market
Europe's scientific institutions are pushing oncology from genomics to multi-omics and from diagnostics to theranostics:
• AI-based pathology and imaging systems reducing diagnostic errors
• Epigenomic markers entering mainstream colorectal and lung cancer workflows
• CRISPR & gene-editing research hubs supporting next-decade therapeutics
• Hybrid biomarker panels combining ctDNA, CTCs, RNA, and methylation signatures
A turning point came when Thermo Fisher launched its multi-omics Oncomine platform in April 2025.
Another came when Datroway, a biomarker-driven ADC, secured FDA approval, validating the biomarker-first oncology model Europe is already preparing to scale.
Precision oncology is no longer limited to major cancer centers - it is moving into regional hospitals, community providers, and even home-based monitoring ecosystems.
Europe's Competitive Landscape | Precision Becomes the Differentiator
Europe's precision oncology supply chain features global giants and specialist innovators:
Tier-1 diagnostic and therapeutics leaders active in Europe
Illumina • Roche & Foundation Medicine • Thermo Fisher • Agilent • Qiagen • AstraZeneca • Novartis • Pfizer • Merck
Tier-2 precision platforms and liquid biopsy specialists
Guardant Health • Caris Life Sciences • Natera • Myriad Genetics • Exact Sciences
What's shifting is the basis of competitive advantage:
• Multi-omics depth, not just sequencing volume
• Turnaround time from biopsy to actionable report
• Companion diagnostic partnerships with pharma pipelines
• AI interpretation accuracy, not just test availability
• Real-world evidence (RWE) integration
• Reimbursement-aligned economics
In Europe, precision oncology is becoming a data-diagnostic-drug continuum, not a set of standalone tools.
The Real Friction | Cutting-Edge Science Meets Real-World Budgets
The biggest obstacle is not biology - it is economics.
Comprehensive genomic profiling costs $3,000-$5,000 per patient, and reimbursement remains inconsistent across EU states.
Foundation Medicine's delayed uptake in several European markets due to reimbursement gaps is a warning signal.
Under-funded systems risk creating a two-tier oncology ecosystem:
those who access precision medicine... and those who receive generalized care.
The irony is that precision oncology reduces long-term costs - fewer ineffective drugs, fewer complications, fewer hospitalizations.
Europe's challenge is shifting budgeting from " upfront cost " to " total value over the patient pathway. "
Buy Now: https://marketgenics.co/buy/precision-oncology-market-55206
What This Means for Decision-Makers | A Boardroom Issue, Not a Lab Issue
Forward-looking European health leaders are revising core questions:
Not:
"How do we lower testing costs?"
But:
"How much waste do we eliminate by matching the right therapy first?"
"How does multi-omics reduce relapse rates, toxicity, and hospital burden?"
"How do biomarker-based pathways improve survival and system efficiency?"
Precision oncology now influences:
• Treatment accuracy
• Mounting demand for targeted therapies
• Clinical trial matching
• Health-system budgeting
• Regulatory exposure
• Pharmaceutical R&D economics
The financialization of precision medicine has begun - and the organizations mastering data, diagnostics, and drug alignment will define Europe's next decade of oncology leadership.
The Hidden Enabler Europe Cannot Ignore
Precision oncology is no longer a niche specialty.
It is the backbone of:
• Europe's cancer-mortality reduction targets
• National genomic medicine programs
• Advanced ADC and immunotherapy pipelines
• Early detection and recurrence monitoring
• Real-world evidence generation for regulators
• Multi-country cancer data platforms
Europe's oncology transition will not be solved by drugs alone.
It requires accuracy - in diagnosis, in biomarker mapping, in therapy selection.
Precision oncology is where billions in system savings and life-years gained converge.
Cancer care is not just treated anymore.
It is profiled, interpreted, and personalized - for outcomes, for economics, and for the future of European healthcare.
----------------------
About Us
MarketGenics is a global market research and management consulting company empowering decision makers across healthcare, technology, and policy domains. Our mission is to deliver granular market intelligence combined with strategic foresight to accelerate sustainable growth.
We support clients across strategy development, product innovation, healthcare infrastructure, and digital transformation.
Contact:
Mr. Debashish Roy
MarketGenics Research
800 N King Street, Suite 304 #4208, Wilmington, DE 19801, United States
USA: +1 (302) 303-2617
Email: sales@marketgenics.co
Website: https://marketgenics.co
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Precision Oncology Market | Europe's Precision Pivot Accelerates - Genomics, Liquid Biopsy & AI Diagnostics Gain Ground While Health Systems Struggle With Cost, Access & CDx Adoption here
News-ID: 4312587 • Views: …
More Releases from MarketGenics Research
Healthcare Contract Manufacturing Market | Europe's Race for Quality-Centric Man …
Healthcare Contract Manufacturing Market | Europe's High-Precision Manufacturing Pivot Is Reshaping the Future of Therapeutics
The Healthcare Contract Manufacturing Market used to live in the operational shadows - a technical appendix to pharma strategy, an afterthought to medical device roadmaps.
That era is gone.
Europe's push for biologics scale-up, GMP modernization, sterile manufacturing compliance, and resilient supply chains has moved the Healthcare Contract Manufacturing Market from the backroom of operations into the center…
"Aerosol Cans Market in Europe: Sustainability, Aluminum Demand, and Regional Gr …
The world is moving fast on sustainability-biodegradable materials, reusable packaging, and recyclable metals are capturing headlines. Aerosol cans, often overlooked as simple packaging, have quietly evolved into a high-performance, environmentally-conscious solution across personal care, household, healthcare, and industrial sectors.
In 2025, the global Aerosol Cans Market reached USD 14.4 billion, and it is projected to expand to USD 24.0 billion by 2035, growing at a CAGR of 4.7%. For a sector…
Clinical Trial Supplies Market | Europe's New Era of Trial Logistics - Big Pharm …
Clinical Trial Supplies Market | Europe's Supply-Chain Transformation Reshaping the Future of Drug Development
The Clinical Trial Supplies Market used to live in the back rooms of pharma operations - cartons, kits, comparators, storage rooms and shipping labels.
That era is gone.
Europe's pivot toward precision medicine, biologics, decentralized studies, and multi-country regulatory complexity has pushed the Clinical Trial Supplies Market from a logistics afterthought into a strategic pillar of clinical success.
This shift…
Clinical Trial Supplies Market | Europe's Supply-Chain Reinvention - Cold-Chain …
The Clinical Trial Supplies Market used to be a logistics afterthought: labelled vials, dry ice shipments, and predictable pallet runs. That era is gone.
Europe's regulatory complexity, the explosion of biologics and cell & gene therapies, and the rise of decentralized clinical trials (DCTs) have moved the Clinical Trial Supplies Market from a vendor line-item into a strategic capability that determines trial speed, quality and cost. From cryogenic storage in Frankfurt…
More Releases for Europe
2019 Strategy Consulting Market Analysis | McKinsey, The Boston Consulting Group …
Strategy Consulting Market reports also offer important insights which help the industry experts, product managers, CEOs, and business executives to draft their policies on various parameters including expansion, acquisition, and new product launch as well as analyzing and understanding the market trends
Need for strategic planning in highly competitive environment and to develop business capabilities to meet & exceed the emerging requirements are the major drivers which help in surging…
Strategy Consulting Market 2025 | Analysis By Top Key Players: Booz & Co. , Rola …
Global Strategy Consulting Market 2019-2025, has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
The key players covered in this study
McKinsey , The Boston Consulting Group , Bain & Company , Booz & Co. , Roland Berger Europe…
Digital Strategy Consulting Market is Thriving Worldwide with Deloitte, McKinsey …
A Digital Strategy is a form of strategic management and a business answer or response to a digital question, often best addressed as part of an overall business strategy. A digital strategy is often characterized by the application of new technologies to existing business activity and focus on the enablement of new digital capabilities to their business.
A new report as a Digital Strategy Consulting market that includes a comprehensive analysis…
Strategy Consulting Market 2019: By McKinsey, The Boston Consulting Group, Bain …
This report studies the global Strategy Consulting market, analyzes and researches the Strategy Consulting development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like
• McKinsey
• The Boston Consulting Group
• Bain & Company
• Booz & Co.
• Roland Berger Europe
• Oliver Wyman Europe
• A.T. Kearney Europe
• Deloitte
• Accenture Europe
Get Sample Report@ https://www.reporthive.com/enquiry.php?id=1247388&req_type=smpl&utm_source=AB
Market segment by Type, the product can be split into
• Operations Consultants
• Business Strategy Consultants
• Investment Consultants
• Sales and…
Strategy Consulting Market Analysis 2018: McKinsey, The Boston Consulting Group, …
Orbis Research Present’s “Global Strategy Consulting Market” magnify the decision making potentiality and helps to create an effective counter strategies to gain competitive advantage.
The global Strategy Consulting status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Strategy Consulting development in United States, Europe and China.
In 2017, the global Strategy Consulting market size was million US$ and it is expected to reach million…
Influenza Vaccination Market Global Forecast 2018-25 Estimated with Top Key Play …
UpMarketResearch published an exclusive report on “Influenza Vaccination market” delivering key insights and providing a competitive advantage to clients through a detailed report. The report contains 115 pages which highly exhibits on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability. This report focuses on the Influenza Vaccination market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This…
